Conversion calendar in hand: management narrates the coming year as dated deliveries of business already secured
The model's full reasoning — Q3 2016 call → NOThe question asks whether management lays out a timetable of specific conversions - identified pieces of business already secured or in motion, each attached to an approximate time frame, so the forward story reads as a schedule of things turning on. Looking at the transcript, management discusses: - Margetuximab Phase 3 SOPHIA trial - enrolling patients, ~90% sites activated, expects to provide more precision on enrollment completion and readout at R&D Day in December. Futility analysis expected in 2017. - MGA012 IND cleared by FDA, working to start Phase 1 trial - no specific timing given for when it starts contributing. - MGD014 IND expected in first half of 2017 (infectious disease program, funded by NIAID). - MGD013 IND expected in 2017 (PD-1 x LAG-3 DART). - MGD010 - regained rights from Takeda, completed dosing in final cohort, data expected first half of 2017. - Enoblituzumab combination studies advancing to dose expansion. - MGD006, MGD007 - clinical updates at R&D Day or first half 2017. The question asks about "conversions" - identified pieces of business already secured that will start contributing on a timetable. The items mentioned are mostly clinical trial progress, IND filings, and data readouts. These are not "conversions" in the sense of secured business contributing revenue or results. IND filings are regulatory submissions, not secured business. Clinical trial enrollment is ongoing, not a conversion. The forward story here is about clinical development milestones - data readouts, IND filings, trial expansions - not about secured business converting to revenue or results. The company is a biotech in development stage, so the "conversions" would be things like trial completions, data readouts, regulatory approvals - but these are not "already secured" business in the sense the question means. The question asks about "identified pieces of business that are ALREADY SECURED OR ALREADY IN MOTION, each attached to an at-least-approximate time frame in which it starts contributing." The items here are clinical trials and IND filings - these are in motion but they are not "conversions" that start contributing to results in a scheduled way. The company's forward story is about pipeline progress, not about scheduled conversions of secured business.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
CPK · Q3 2017 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured business and approximate time frames.
SOL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.
FLL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.